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INTRODUCTION
Recently, concerns have been raised as to whether external factors, including lack of adherence to csDMARD therapy, might reduce the anticipated benefit associated with use of biologic agents if patients discontinue use of a concomitant csDMARD. Evidence from real-life registry data shows that approximately one-third of RA patients treated with biological agents use 5 them as monotherapy and that when MTX is prescribed in combination with a biological agent, more than half of the patients do not take MTX as prescribed {Emery, 2013 2499 /id}.
As most biological agents have shown more favourable results in combination with csDMARD therapy {Singh, 2009 1746 /id}, and many RA patients might not adhere to their MTX prescription, it is important to evaluate the benefit and harm associated with use of biological agents as monotherapy, and not only the traditional combination therapy strategies {Bergman, 2010 1744 /id; Guyot, 2011 Guyot, 2376 Guyot, 2012 Guyot, 2375 . Therefore, the objective of this study was to assess the efficacy and safety of the individual biological agents applied as monotherapy in patients with RA to inform decision makers on the relative effectiveness of biological agents used in monotherapy.
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METHODS
A network meta-analysis of randomised trials combined direct and indirect evidence. Methods of analysis and inclusion criteria were specified in advance and documented in a protocol (PROSPERO 2012:CRD42012002800) . Both protocol and analyses were prepared according to the 'Methodological Expectations for Cochrane Intervention Reviews' (MECIR) program. Our study conforms to the PRISMA guidelines for reporting systematic reviews {Liberati, 2009 2163 /id}.
Literature search
We searched The Cochrane Central Register of Controlled Trials, Medline, Embase, and ClinicalTrials.gov for published reports from inception of each database through December 16, 2014 (Supplement Table 1 ). We combined terms for rheumatoid arthritis with the nine biological agents of interest (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, and tocilizumab) . Search results were limited to randomised controlled trials (RCTs) by applying appropriate filters. We then collated additional reports identified in relevant systematic reviews not retrieved through the electronic databases. We also scrutinized relevant reports on FDA's and EMA's websites and searched relevant pharmaceutical companies' websites to identify unpublished trial data.
Trial selection
Double-blind randomised trials studying the administration of one of the eligible biological agents were considered eligible if they were used as monotherapy in an (FDA/EMA)-approved route of administration in RA patients. Trials were considered eligible if at least one within-study comparison was available with placebo, MTX, or another approved biological agent as monotherapy. We did not include open label trials, trials with no full English text available, trials not reporting ACR50 responses, trials comparing the same biological agent with and without MTX, or trials comparing different doses of the same biological agent in monotherapy.
Outcome measures
The core-outcome data in each study consist of the sample size of the groups and the number of patients in each group who met the predefined outcomes of interest. A priori it was decided to use the outcome assessment at 6 months, if available. If 6 months data were unavailable, we used data closest to 6 months in each trial. Two major outcomes were considered co-primary 
Data collection and risk-of-bias assessment
Outcome measure extractions were based on the intention-to-treat (ITT) population whenever possible. Two independent reviewers (ST and AD) extracted all the data. Data were collected on the general characteristics of the RCT and sample size. The interventions being compared were extracted, including dosages and frequency of the administered drugs.
The internal validity of the included studies was evaluated on the basis of the apparent risk of bias within each RCT; domains (including selection bias, performance bias, detection bias, attrition bias, and reporting bias) were assessed using the items of the risk-of-bias tool as recommended by the Cochrane Collaboration {Higgins, 2011 1853 /id}.
Data synthesis and analysis
We used random effects meta-analyses by default, assuming the true treatment effect differs from study to study {Riley, 2011 2502 /id}. Unlike a contrast-based (standard) meta-analysis approach {DerSimonian, 1986 525 /id}, an arm-based approach was used to include multiple comparisons in the network meta-analysis {Salanti, 2008 2039 /id} in order to combine both direct and indirect comparisons. We performed mixed-effects logistic regression using an (arm-based) random effects model within an empirical Bayes framework {Singh, 2009 1746 /id; Platt, 1999 2711 /id}. The generalised linear mixed model (GLMM) incorporates a vector of random effects and a design matrix for the random effects {Platt, 1999 2711 /id}. Allowance was made for differences in heterogeneity of effects between different drugs by specifying that the linear predictor varies at the level of study and as an interaction between study and drug. In the network meta-analyses, we measured heterogeneity (i.e., between-study variance) for the analysis using T 2 (an estimate for Tau-squared), which examines heterogeneity because of Study and Study×Drug
interaction (smaller values indicate a better model per se).
Sensitivity analyses
Post hoc sensitivity analyses on the primary outcomes were conducted to explore impact of csDMARD history and dose: (i) exclusion of studies not evaluating csDMARD inadequate responder 9 patients; (ii) exclusion of trial arms not evaluating an FDA-or EMA-recommended average maintenance dose (defined in Supplement Table 2), including MTX comparator trial arms not evaluating an oral MTX dose of at least 10 mg weekly (or subcutaneous in equivalent dose). If only one trial arm evaluated a recommended dose, the whole study was excluded from the sensitivity analysis (placebo trial arms [i.e., no biological or csDMARD treatment] were categorised as recommended dose for technical reasons). (Table 1; references available in Supplement Table 3 ). 
Benefit and harm according to primary outcomes
As illustrated in Figure 3A , most biological agents (as well as MTX) were statistically significantly more likely than placebo to lead to an ACR50 response; exceptions were anakinra and infliximab.
Of the 28 included studies (all reporting ACR50), 24 reported withdrawals because of adverse events. Compared to placebo, withdrawals because of adverse events were not statistically significantly higher among patients for any of the drugs ( Figure 3B ). For sensitivity, direct pairwise meta-analyses were conducted for both primary benefit and harm outcome. As presented in Supplement Figure 1-4 , estimates from the network meta-analysis were in agreement with the direct evidence (i.e., point estimate from the network meta-analysis were included within the 95%CI of the direct estimate). The only exception was tocilizumab compared with placebo for withdrawal because of adverse events, where the point estimate from the network meta-analysis (1.84) was not included within the 95%CI of the direct estimate (0.04 to 1.29). Further, for benefit the direct pairwise meta-analysis found relevant inconsistency for certolizumab pegol compared with placebo (I 2 =71%), with no obvious explanation. Relevant inconsistency was also found for etanercept and tocilizumab compared with MTX (I 2 =83% and 80% respectively), probably explained by the low MTX dose (8 mg weekly) used in two Japanese trials (etanercept {Takeuchi, 2012}; tocilizumab {Nishimoto, 2009}. These two trials were excluded in the sensitivity analysis of recommended dose. For harm, relevant inconsistency was also found for etanercept compared with MTX (I 2 =79%), probably explained be the low MTX dose applied in the Japanese trial. Etanercept was more likely to lead to clinical response than anakinra (OR=3.38; 95% CI, 1.26 to 9.01) and MTX (1.54; 1.03 to 2.32; Figure 4) . Rituximab also appears more effective than anakinra (Figure 4) , none of the drugs included in the network appeared more likely than others to lead to discontinuation due to adverse events. 
Benefit and harm according to secondary outcomes
From the primary analysis, based on the primary benefit-outcome, statistical evidence suggested etanercept to be more efficacious than anakinra and MTX. In secondary outcome analyses, this finding was supported for ACR20 but not for ACR70, where etanercept was not statistically significantly different from MTX (1.47; 0.92 to 2.36) (Supplement Table 4 ). Rituximab was statistically significantly superior to anakinra for the primary benefit-outcome, which was supported by analyses of ACR20 and ACR70. Tocilizumab was statistically superior to adalimumab, anakinra, certolizumab pegol, golimumab, and MTX for ACR50, an effect that appeared robust when ACR20 and ACR70 rates were evaluated (Supplement Table 4 ) with one exception; tocilizumab was not statistically significantly superior to golimumab (1.85; 0.97 to 3.52).
When secondary harm measures, SAEs, and the total number of withdrawals (Supplement Table 5 ) were examined, no statistically significant differences occurred for SAEs (anakinra was not included due to lack of reporting). For the total number of withdrawals, tocilizumab was statistically significantly more favourable than abatacept, adalimumab, anakinra, and MTX.
Sensitivity analyses in trials using the recommended dose
When the analysis of the primary benefit outcome (ACR50) was based on treatment with the recommended maintenance dose (Supplement Table 6 ), anakinra and infliximab were not included, as these biological agents were not evaluated at the recommended doses. The apparent superiority of etanercept over MTX could not be confirmed statistically for its recommended dose (OR= 1.25; 0.90 to 1.72). However, in its recommended dose, etanercept was now more likely to lead to clinical response than adalimumab and certolizumab pegol. The findings for tocilizumab appeared robust, with superiority over adalimumab, certolizumab pegol, and MTX. However, the apparent superiority of tocilizumab over golimumab could not statistically be confirmed for recommended dose (OR= 2.07; 0.89 to 4.85). Monitoring harms by proxy according to all comparisons (Supplement Table 6 ), adalimumab, etanercept, tocilizumab at their recommended doses, and MTX (≥10 mg weekly) were all more likely than placebo to lead to discontinuation due to adverse events. However, no differences among any biological agents or MTX were statistically significant.
Sensitivity analyses among DMARD-IR patients
When the analysis of the primary benefit outcome (ACR50) was based on studies of patients who had had an inadequate response to csDMARDs (DMARD-IR; see Supplement Table 7 ), the findings for etanercept were robust as it was still more likely to lead to clinical response than anakinra and MTX. The apparent superiority of rituximab over anakinra could not be statistically confirmed (3.03; 0.66 to 14.29). Also, the findings for tocilizumab appeared robust, with superiority over adalimumab, anakinra, golimumab, and MTX. However, the apparent superiority of tocilizumab over certolizumab pegol could not be confirmed in the sensitivity analysis based on DMARD-IR patients only (2.18; 0.89 to 5.32).
Further, to explore how much impact the only "biologics head-to-head" comparison study (ADACTA) {Gabay, 2013 2418 /id} had on the estimates in the network, the DMARD-IR sensitivity analyses were performed with exclusion of the ADACTA study on tocilizumab against adalimumab in DMARD-IR patients (Supplementary Table 8) , revealing sparse data supporting superiority of tocilizumab compared with other biological agents prior to the ADACTA study (e.g., vs. adalimumab 1.81; 0.80 to 4.15). In the ADACTA study, tocilizumab was statistically significantly superior to adalimumab (2.33; 1.47 to 3.69).
DISCUSSION
This study suggests there are differences in effectiveness but not in harm among biological agents applied as monotherapy in RA. Patient-important benefits such as ACR50 occurred more frequently with etanercept or tocilizumab monotherapy than with other biological agents.
Although tocilizumab was superior to a higher number of agents than the number etanercept was superior to, no statistically significant difference between tocilizumab and etanercept was found throughout the conducted analyses. Further, in recommended dose, both etanercept and tocilizumab were superior to adalimumab and certolizumab pegol. Despite rituximab's being superior to anakinra, had response rates comparable to etanercept and tocilizumab against placebo, and no differences between rituximab and etanercept or tocilizumab were found, evidence on rituximab was based on one study only, where 40 patients were treated with rituximab monotherapy, thereby limiting our confidence in these findings. Our evidence synthesis also has limitations. The included studies span a 17-year period, from 1998 through 2015; so patients enrolled in early studies may differ from those included in more recent studies. Moreover, the RA patients enrolled in the different monotherapy studies are to some extent heterogeneous (encompassing different duration of diseases and differences in the extent of prior MTX failure). Further, only one head-to-head trial was identified, reducing our confidence in the comparative estimates. In other words, future biological agent monotherapy head-to-head trials will likely have an important impact on our estimates. A priori, we defined a hierarchical list of outcomes, giving priority to 6 months data when available. When they were not available, other time points were used (e.g., nine studies lasted only 16 weeks or less, and in six studies safety data were available only after one year or more. Comparisons among studies across different time points could potentially limit the interpretation of our results. Further, whether our results can be extrapolated to long-term efficacy and safety is not clear.
In conclusion, trial evidence suggests etanercept or tocilizumab to be the most appropriate choice to RA patients treated with biological monotherapy.
